We first assessed IFN-γ responses to the four DENV serotypes in PBMCs collected before or after symptomatic secondary DENV2 (19 PBMCs from 10 patients) and DENV3 (8 PBMCs from 4 patients) infections using an ex-vivo ELISPOT assay (Figure S2). This evidence concerns the gene IFNG and infection.